Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial

Publication | Open Access

DOI Full Paper Access

Citations

References

2017

Year

Pedro Cahn, Richard Kaplan, Paul E. Sax, Kathleen Squires, Jean‐Michel Molina, Anchalee Avihingsanon, Winai Ratanasuwan, Evelin Rojas, Mohammed Rassool, Mark Bloch,

The Lancet HIV

Treatment And PreventionAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyVirologyRaltegravir 1200PharmacotherapyHiv-1 InfectionAntiviral DrugHivMedicinePhase 3